Laekna, Inc. (China)

Alternate names: Laekna, Laekna Limited, Laekna, Inc.

ROR: 004x2vd92

OpenAlex ID: I4405266875

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

2022 · Jing Xu, Yi Gao, et al. · Cancer Chemotherapy and Pharmacology · 17

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

2021 · Xiaoxi Dong, Tiantian Zheng, et al. · Frontiers in Oncology · 15

PDF

An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)

2025 · Thomas J. Herzog, John B. Liao, et al. · Gynecologic Oncology · 4

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

2026 · Pin Zhang, Tao Sun, et al. · Nature Communications · 3

PDF

Abstract 7132: Preclinical characterization of LAE119, a novel PARP1 selective inhibitor and trapper

2024 · Ming Li, Yan Chen, et al. · Cancer Research · 2

Abstract LB437: LAE118, a pan mutant-selective PI3Ka inhibitor with superb activity against both the kinase domain and helical domain mutants

2025 · Ming Li, Ruipeng Zhang, et al. · Cancer Research · 1

Abstract 670: Preclinical candidate LAE120, a novel selective USP1 inhibitor shows effective anticancer and combination activity with PARP inhibitor

2024 · Jintao Wang, Yan Chen, et al. · Cancer Research · 1

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care

2023 · E. Diamond, C. Kwak, et al. · Annals of Oncology · 1

PDF

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

2021 · A. Bessudo, X. Wang, et al. · Annals of Oncology · 1

PDF

Abstract 4192: Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors

2025 · Ming Li, Minhua Zhang, et al. · Cancer Research

EV103/#405 A phase I/II dose-escalation and efficacy/safety study of afuresertib plus sintilimab plus nab-paclitaxel in solid tumors primarily cervical cancer and endometrial cancer

2024 · Lin Shen, Rutie Yin, et al. · International Journal of Gynecological Cancer

PDF

370P A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects

2024 · P. Zhang, B. Xu, et al. · Annals of Oncology

Abstract PS17-08: A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

2024 · Binghe Xu, Pin Zhang, et al. · Cancer Research

Abstract CT128: Phase I/II clinical trials of LAE005, afuresertib plus nab-paclitaxel in patients with advanced solid tumors, primarily in patients with triple-negative breast cancer (TNBC)

2024 · Binghe Xu, Pin Zhang, et al. · Cancer Research

473 LAE113, a novel TIGIT/PVRIG bispecific antibody for the treatment of cancer

2023 · Yan Chen, Xue Li, et al. · Journal for ImmunoTherapy of Cancer

PDF

575 Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody

2023 · Minhua Zhang, Rong Wu, et al. · Journal for ImmunoTherapy of Cancer

PDF

597P A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)

2021 · D. Ye, R. Liu, et al. · Annals of Oncology

PDF

Abstract 551: Clinical utility of cell-free DNA based PTEN copy number loss in prostate cancer

2021 · Xiaoxi Dong, Minghua Zhang, et al. · Cancer Research

180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer

2020 · Y. Yue, H. Shen, et al. · International Journal of Gynecological Cancer

PDF

Works count: 19

Citation count: 156